SMAD2 and Patent ductus arteriosus: These same genomic analyses have also identified homozygous deletions in a series of other known (e.g., SMAD2, SMAD3, JARID2) and putative (SMYD3, USP25) tumor suppressor genes that are selectively disrupted in PDA genomes.